Business & Finance
Halozyme Therapeutics reports Q2 2021 financial results
10 August 2021 -

Halozyme Therapeutics Inc (NASDAQ: HALO), a United States-based biopharmaceutical company, has reported its financial results for the second quarter ended 30 June 2021, on Monday.

The company reported revenue for the second quarter of 2021 at USD136.5m, compared to USD55.2m for the same period in 2020. It reported net income on a GAAP basis for the period at USD91.5m compared to net income of USD25.8m for the same period in 2020.

On a GAAP basis for the second quarter of 2021, diluted earnings per share was USD0.62 compared with USD0.19 for the second quarter of 2020. The company posted non-GAAP basis diluted earnings per share at USD0.66 against diluted earnings per share of USD0.24 in the same period in 2020.

'Our excellent start to 2021 continued in the second quarter with strong quarterly growth resulting in record quarterly revenues from royalties and the signing of our eleventh collaboration and license agreement,' said Dr Helen Torley, president and chief executive officer. 'Our recently announced collaboration with ViiV Healthcare demonstrates the potential for our ENHANZE technology to meet evolving patients' needs by creating long-acting drugs that facilitate rapid, large volume subcutaneous injections of small molecule drugs. This collaboration also highlights the potential for ENHANZE in new disease areas like infectious disease. As a result of this new collaboration and our strong results to date, we are pleased to share that we are raising our guidance for revenues and earnings for the year.'